@article{374bd9451abe4e6ebbbd8f8ff92518ae,
title = "Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia",
abstract = "The relationship between clinicopathologic diagnosis and 123I-FP-CIT SPECT in 18 patients with dementia (12 with Lewy body disease) from one center in the United States was assessed. The sensitivity and specificity of abnormal 123I-FP-CIT SPECT with reduced striatal uptake on visual inspection for predicting Lewy body disease were 91.7% and 83.3%, respectively. The mean calculated putamen to occipital ratio (mPOR) based on regions of interest was significantly reduced in Lewy body disease compared to non-Lewy body disease cases (P = 0.002). In this study, abnormal 123I-FP-CIT SPECT was strongly associated with underlying Lewy body disease pathology, supporting the utility of 123I-FP-CIT SPECT in the clinical diagnosis of dementia with Lewy bodies.",
author = "Youngsin Jung and Jordan, {Lennon G.} and Lowe, {Val J.} and Kejal Kantarci and Parisi, {Joseph E.} and Dickson, {Dennis W.} and Murray, {Melissa E.} and Reichard, {Ross R.} and Ferman, {Tanis J.} and Jones, {David T.} and Jonathan Graff-Radford and Rodolfo Savica and Machulda, {Mary M.} and Fields, {Julie A.} and Allen, {Laura A.} and Drubach, {Daniel A.} and {St. Louis}, {Erik K.} and Silber, {Michael H.} and Jack, {Clifford R.} and Knopman, {David S.} and Petersen, {Ronald C.} and Boeve, {Bradley F.}",
note = "Funding Information: Youngsin Jung, Lennon G. Jordan III, Joseph E. Parisi, Dennis W. Dickson, Melissa E. Murray, Ross R. Reichard, Tanis J. Ferman, David T. Jones, Jonathan Graff-Radford, Rodolfo Savica, Mary M. Machulda, Julie A. Fields, Laura A. Allen, Daniel A. Drubach and Michael H. Silber had nothing to disclose. Val J. Lowe serves on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences which hold patents for and sells PET radiopharmaceuticals; receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH. Kejal Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc., and receives research support from the NIH. Erik K. St. Louis serves as consultant for Axovant, Inc.; receives research support from Mayo Clinic CCaTS, NIH/NINDS, NIH/NHLBI, Axovant, Inc., and Sunovion, Inc.; and receives book royalties from Wiley-Blackwell. Clifford R. Jack, Jr. serves on scientific advisory board for Eli Lilly & Company; receives research support from the NIH/NIA, and the Alexander Family Alzheimer{\textquoteright}s Disease Research Professorship of the Mayo Foundation; and holds stock in Johnson & Johnson. David S. Knopman serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals, Biogen, and the Alzheimer{\textquoteright}s Disease Cooperative Study; and receives research support from the NIH. Ronald C. Petersen serves on data monitoring committees for Pfizer, Inc., Janssen Alzheimer Immunotherapy, and is a consultant for Biogen, Roche, Inc., Merck, Inc., and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and receives research support from the NIH. Bradley F. Boeve is investigator for clinical trials sponsored by GE Healthcare and Axovant; receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2016); serves on the Scientific Advisory Board of the Tau Consortium; receives research support from the NIH, Mangurian Foundation, and the Little Family Foundation. Role of Sponsor: The staff at GE Healthcare was neither involved in the analysis and interpretation of the data nor in the preparation of this manuscript. Funding Information: This study was supported by GE Healthcare, NIH grants AG015866, AG016574, and UL1 TR000135, the Man-gurian Foundation, an anonymous donor, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer{\textquoteright}s Disease Research Program of the Mayo Foundation. We thank the staff of Mayo Alzheimer{\textquoteright}s Disease Research Center and especially the subjects and family members involved in the study. Publisher Copyright: {\textcopyright} 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",
year = "2018",
month = mar,
doi = "10.1002/acn3.521",
language = "English (US)",
volume = "5",
pages = "376--381",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",
number = "3",
}